Gilead has been rewarded handsomely, via share price gains, for its Covid-19 remdesivir work, but the potential costs should not be forgotten.
With the prevalence of coronavirus infection running at about 5%, test manufacturers and regulators alike will have to guard against false positives.
Industry-sponsored clinical studies against the new coronavirus have proliferated, as have their designs and efficacy measures.
What is biopharma doing to develop vaccines against Covid-19, and what are the properties of each approach? Vantage takes a look.
Sales of implants are set to fall sharply as non-urgent procedures are deferred.
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
As Smiths Group delays its split partly so it can focus on ventilator production, the US FDA grants emergency authorisation to other breathing devices to treat Covid-19.
Good news for patients whose cough is not caused by Covid-19: Merck’s chronic cough pill is a step closer to market. But tolerability questions remain.
A Vantage analysis suggests which small biotechs might seriously have to rethink R&D spending plans in the wake of Covid-19.